

28th February 2025

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500674

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra East,
Mumbai 400 050

Symbol: SANOFI

Sub: Integrated Filing (Financial) for the quarter and year ended 31st December 2024

Dear Sirs/Madam,

Pursuant to Regulation 10(1A) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January 2025, we enclose herewith the Integrated Filing (Financial) for the guarter and year ended 31st December 2024.

Please take the above information on record.

Thanking you,

Yours faithfully For **Sanofi India Limited**

Rachid Ayari
Whole-time Director and Chief Financial Officer
DIN: 10408699



Integrated Filing (Financial) for the guarter and year ended 31st December 2024

- A. Financial Results: Refer Annexure A
- B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc: Not Applicable
- C. Format for disclosing Outstanding Default on Loans and Debt Securities

S. No.	Particulars	in INR crore										
1.	Loans / revolving facilities like cash credit from banks / financial institutions											
Α	Total amount outstanding as on date	NIL										
В	Of the total amount outstanding, amount of default as on date	NIL										
2.	Unlisted debt securities i.e. NCDs and NCRPS											
Α	Total amount outstanding as on date	NIL										
В	Of the total amount outstanding, amount of default as on date	NIL										
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	NIL										

- D. Format for Disclosure of Related Party Transactions For the Quarter and Year ended December 31, 2024: Refer Annexure B
- E. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion)
 Submitted along- with Annual Audited Financial Results: Not Applicable

Annexure A

Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Sanofi India Limited

Report on the Audit of Standalone Financial Results

Opinion

- 1. We have audited the standalone annual financial results of Sanofi India Limited (hereinafter referred to as the 'Company") for the year ended December 31, 2024 and the standalone statement of assets and liabilities and the standalone statement of cash flows as at and for the year ended on that date, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations') which has been digitally signed by us for identification purposes.
- In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended December 31, 2024 and the standalone statement of assets and liabilities and the standalone statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Price Waterhouse & Co Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West) Mumbai - 400 028

T: +91 (22) 66697508

Registered office and Head Office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) Converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

INDEPENDENT AUDITOR'S REPORT To the Board of Directors of Sanofi India Limited Report on the Standalone Financial Results Page 2 of 4

Board of Directors' Responsibilities for the Standalone Financial Results

- These Standalone financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the standalone statement of assets and liabilities and the standalone statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the standalone financial results by the Directors of the Company, as aforesaid.
- 5. In preparing the standalone financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
- 6. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

7. Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

INDEPENDENT AUDITOR'S REPORT To the Board of Directors of Sanofi India Limited Report on the Standalone Financial Results Page 3 of 4

- 8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls. (Refer paragraph 11 below)
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- 9. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

INDEPENDENT AUDITOR'S REPORT To the Board of Directors of Sanofi India Limited Report on the Standalone Financial Results Page 4 of 4

Other Matters

- 10. The Financial Results include the results for the quarter ended December 31, 2024 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which are neither subject to limited review nor audited by us.
- 11. The standalone annual financial results dealt with by this report has been prepared for the express purpose of filing with National Stock Exchange of India Limited and BSE Limited. These results are based on and should be read with the audited standalone financial statements of the Company for the year ended December 31, 2024, on which we issued an unmodified audit opinion vide our report dated February 27, 2025.

For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026E/ E-300009

ARUNKUMA Digitally signed by ARUNKUMAR RAMDAS

RAMDAS Date: 2025.02.27 21:04:18 +05'30'

Arunkumar Ramdas Partner Membership Number: 112433 UDIN: 25112433BMOUXC3152

Place: Mumbai

Date: February 27, 2025

Registered Office : Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072. Corporate Identity Number: L24239MH1956PLC009794

Tel no: (91-22) 28032000 Fax No: (91-22) 28032846 Website: www.sanofiindialtd.com Email: igrc.sil@sanofi.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024

₹ in Million

Particulars	Quarter ended 31.12.2024 (Unaudited)	Quarter ended 30.09.2024 (Unaudited)	Quarter ended 31.12.2023 (Unaudited)	Year ended 31.12.2024 (Audited)	Year ended 31.12.2023 (Audited)
	(Refer Note 3 and 8)	(Refer Note 3)	(Refer Note 3 and 8)		(Refer Note 3)
Continuing Operations	,				
1. Revenue from Operations	5,149	5,240	4,692	20,132	19,961
2. Other Income	59	23	94	165	612
3. Total Income (1+2)	5,208	5,263	4,786	20,297	20,573
4. Expenses					
(a) Cost of Materials Consumed (b) Purchases of stock in trade (c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods (d) Employee benefits expense (e) Finance costs (f) Depreciation and amortisation expense (g) Other expenses	1,027 2,385 (914) 538 4 96 930	931 2,018 (349) 567 4 90 876	783 1,278 133 725 4 93 777	3,548 5,643 602 2,402 15 367 3,029	3,439 8,933 (2,837) 2,807 17 365 2,742
Total Expenses	4,066	4,137	3,793	15,606	15,466
5. Profit before exceptional items and tax from continuing operations (3-4)	1,142	1,126	993	4,691	5,107
6. Exceptional items (Refer note 6)	80	-	-	(377)	178
7. Profit before tax from continuing operations (5+6)	1,222	1,126	993	4,314	5,285
8. Tax expense from continuing operations Current Tax Deferred Tax	279 30	310 (6)	271 25	1,258 (81)	1,634 5
9. Profit for the period /year from continuing operations (7-8)	913	822	697	3,137	3,646
10. Profit before tax from discontinued operations	-	-	895	1,312	3,173
11. Tax expense from discontinued operations	-	-	215	314	787
12. Profit for the period /year from discontinued operations (10-11)	-	-	680	998	2,386
13. Profit for the period /year (9+12)	913	822	1,377	4,135	6,032
14. Other comprehensive income (OCI) (Net of Tax) from continuing operations	72	-	(13)	72	(13)
15. Other comprehensive income (OCI) (Net of Tax) from discontinued operations	-	-	-	-	-
16. Total Other comprehensive income (OCI) (Net of Tax) (14+15)	72	-	(13)	72	(13)
17. Total comprehensive income for the period/year (13+16)	985	822	1,364	4,207	6,019
18. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230
19. Other equity	-	-	-	8,376	9,925
20. Basic and diluted earnings per share (not annualised) (in ₹) Continuing Operations Discontinued Operations Continuing and Discontinued Operations	39.64 - 39.64	35.69 - 35.69	30.26 29.53 59.79	136.21 43.33 179.54	158.31 103.60 261.91

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 27, 2025





STANDALONE STATEMENT OF ASSETS AND LIABILITIES

₹ in Million

STANDALONE STATEMENT OF ASSETS AND LIABILITIES		₹ in Million
	As at December 31, 2024 Audited (Refer Note 4)	As at December 31, 2023 Audited (Refer Note 4)
ASSETS	(Here: Here I)	(itele itele i)
Non-current assets		
Property, plant and equipment	2,558	2,544
Capital work in progress	181	133
Right-of-use assets	554	556
Intangible assets	13	49
Intangible assets under development	-	26
Financial assets		
(i) Investment in Subsidiary	-	20
(ii) Other financial assets	127	111
Income tax assets (net)	1,375	1,194
Deferred tax assets (net)	1	-
Other non-current Assets	41	55
Total non-current assets	4,850	4,688
Current assets		
Inventories	4,998	6,638
Financial assets		
(i) Trade receivables	2,300	1,317
(ii) Cash and cash equivalents	2,838	3,929
(iii) Bank Balances other than (ii) above	110	120
(iv) Loans	10	19
(v) Other financial Assets	452	78
Other current assets	560	362
Total current assets	11,268	12,463
TOTAL ASSETS	16,118	17,151
EQUITY AND LIABILITIES Equity		
Equity share capital Other equity	230	230
Reserves and surplus	8,376	9,925
Total equity	8,606	10,155
LIABILITIES Non-current liabilities Financial liabilities		
Lease liabilities	140	139
Employee benefit obligations	180	307
Deferred tax liabilities (net) Total non-current liabilities	320	37 483
Total non-current liabilities	320	463
Current liabilities Financial liabilities		
(i) Lease liabilities	53	51
(ii) Trade payables	224	202
(a) Total outstanding dues of micro enterprises and small enterprises	221	283
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	3,842	2,632
(iii) Other financial liabilities	344	167
Provisions Employee hopefit obligations	1,185 540	1,341 928
		1,015
Employee benefit obligations Current tax liabilities (net)	()EA	1.015
Current tax liabilities (net)	959 48	
Current tax liabilities (net) Other current liabilities	48	96
Current tax liabilities (net)		

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should he read in conjunction with the audit report R RAMDAS Date: 2025.02.27 21:05:25 +05'30' purposes only and this Statement should

ARUNKUMA ARUNKUMAR



₹ in Million

Particulars	Year ended December 31, 2024 Audited	Year ended December 31, 2023 Audited				
	(Refer note 3 and 4)	(Refer note 3 and 4)				
Cash flow From operating activities						
Profit before tax :						
Continuing Operations	4,314	5,285				
Discontinued Operations	1,312	3,173				
Profit before income tax including Discontinued Operations	5,626	8,458				
Adjustment for Continuing and Discontinued Operations:						
Depreciation and amortization expenses	382	396				
Unrealised exchange (gain) / loss (net)	6	(4)				
(Gain) on sale of property, plant and equipment / asset held for sale (net of incidental expenses)	(5)					
Gain on termination/retirement of lease (net)	- '	(13)				
Finance costs	15	17				
Interest income	(166)	(475)				
Share based payment	12	61				
Provision for bad and doubtful debts (net)	2	(8)				
Provision for doubtful advances and deposits (net)	5	(4)				
Operating profit before working capital changes	5,877	8,210				
Adjustments for (increase) / decrease in operating assets						
Non-current financial assets	(21)					
Other non-current assets	(7)					
Inventories	687	(2,558)				
Trade receivables	(1,270)	6				
Current financial assets and loans	(357)					
Other current assets Adjustments for increase / (decrease) in enerating liabilities	(898)	101				
Adjustments for increase / (decrease) in operating liabilities Employee benefit obligations	(143)	(268)				
Trade payables	1,662	(669)				
Current financial liabilities	134	40				
Other current liabilities & provisions	(73)	(175)				
Cash generated from operations	5,591	4,721				
Taxes paid (Net of refunds)	(974)					
Net cash inflow from operating activities (A)	4,617	2,308				
Cash flow from Investing activities						
Sale proceeds of property, plant and equipment and assets held for sale (net of incidental expenses)	6	243				
Interest received	166	475				
Investment in Subsidiary	-	(20)				
Purchase of property, plant and equipment and Intangible assets	(364)	(343)				
Net cash (outflow) / inflow for investing activities (B)	(192)	355				
	` '					
Cash flow from financing activities						
Principal elements of lease payments	(63)	(83)				
Interest paid	(15)	(17)				
Dividend paid	(3,846)	(8,683)				
Net cash (outflow) for financing activities (C)	(3,924)					
Net increase / (decrease) in cash and cash equivalents (A+B+C)	501	(6,120)				
Effect of Exchange differences on cash and cash equivalents held in foreign currency	*	*				
Cash and Cash Equivalents at the beginning of the year/period	3,929	10,049				
Less: Cash Transferred pursuant to demerger (Refer Note 4)	(1,592)	-				
Cash and Cash Equivalents at the end of the year	2,838	3,929				
Non- cash financing and investing activities (D)						
Acquisition of Right-of-use assets	66	106				
Components of Cash and Cash Equivalents						
Cash and Cash Equivalents	2,838	3,929				

^{*} denotes figure less than a million.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 27, 2025

RAMDAS

ARUNKUM Digitally signed by ARUNKUMAR RAMDAS Date: 2025.02.27 21:06:02 +05'30'



Date: 2025.02.27 20:32:14 +05'30'

Notes:

- 1. The above Results have been reviewed by the Audit Committee at its meeting held on February 26, 2025 and approved by the Board of Directors of the Company at its Meeting held on February 27, 2025.
- 2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- 3. The Board on May 10, 2023, had approved a Scheme of arrangement under Sections 230 to 232 of the Companies Act, 2013 ("Scheme"), to demerge the Consumer Healthcare business of the Company into its wholly owned subsidiary Sanofi Consumer Healthcare India Limited ("SCHIL"). Pursuant to receipt of necessary statutory approvals and in accordance with the Scheme, the Company has demerged its Consumer Healthcare business effective June 1, 2024, with the Appointed Date being June 1, 2023 as approved by NCLT under the Scheme. Consequently, the financial results of the Consumer Healthcare business for the period upto May 31, 2024 and quarter and year ended December 31, 2023 have been presented as discontinued operations to reflect the impact of this demerger.
- 4. Pursuant to the demerger, the Company has derecognized from its books of account, the carrying amount of assets and liabilities as on May 31, 2024 pertaining to the Consumer Healthcare business transferred to SCHIL. The excess of the carrying amount of assets transferred over the carrying amount of liabilities transferred aggregating to ₹1,902 million has been debited to reserves in accordance with the Scheme.
- 5. The shareholders of the Company were allotted equity shares of SCHIL in accordance with the Scheme. Accordingly, from June 1, 2024, SCHIL ceased to be a subsidiary of the Company.
- 6. Exceptional item for the quarter ended December 31, 2024 of ₹80 million relates to part reversal of personnel separation cost. For the year ended December 31, 2024 exceptional cost relates to personnel separation cost amounting to ₹377 million net of above reversal. Exceptional item for the year ended December 31, 2023 includes profit on sale of property amounting to ₹255 million offset by personnel separation cost amounting to ₹77 million.
- 7. For the continuing business, the Board has recommended maintaining the final Dividend at ₹117 per equity share of ₹ 10 for the year ended December 31, 2024. The dividend will be paid after approval of shareholders at ensuing Annual General Meeting of the Company.
- 8. The figures for the quarter ended December 31, 2024 and December 31, 2023 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2024 and December 31, 2023 and the unaudited published year-to-date figures up to September 30, 2024 and September 30, 2023 respectively, which was subject to limited review, being the date of the end of the third quarter of the said financial year.
- 9. The Company has a single business segment namely 'Pharmaceutical Business'.

SANOFI INDIA LIMITED

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 27, 2025

ARUNKUMA Digitally signed by ARUNKUMAR RAMDAS

R RAMDAS Date: 2025.02.27
21:06:34 +05'30'

RACHID Digitally signed by RACHID AYARI Date: 2025.02.27 20:32:36 +05'30'

RACHID AYARI WHOLETIME DIRECTOR & CFO DIN: 10408699

February 27, 2025

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Sanofi India Limited

Report on the Audit of Consolidated Financial Results

Opinion

- 1. We have audited the consolidated annual financial results of Sanofi India Limited (hereinafter referred to as the 'Holding Company") and its subsidiary (Holding Company and its subsidiary together referred to as "the Group"), (Refer note 1 to the consolidated annual financial results) for the year ended December 31, 2024 and the consolidated statement of assets and liabilities and the consolidated statement of cash flows as at and for the year ended on that date, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations') which has been digitally signed by us for identification purposes.
- 2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial results:
 - (i) include the annual financial results of the following entities

Relationship	Entity Name
Holding Company	Sanofi India Limited
Subsidiary Company	Sanofi Consumer Healthcare India Limited (Upto June 1, 2024 being the date of cessation of being a subsidiary).

- (ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (iii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group, for the year ended December 31, 2024 and the consolidated statement of assets and liabilities and the consolidated statement of cash flows as at and for the year ended on that date.

Price Waterhouse & Co Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West) Mumbai - 400 028

T: +91 (22) 66697508

Registered office and Head Office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) Converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

INDEPENDENT AUDITOR'S REPORT To the Board of Directors of Sanofi India Limited Report on the Consolidated Financial Results Page 2 of 4

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Consolidated Financial Results' section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

- These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group and the consolidated statement of assets and liabilities and the consolidated statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.
- 5. In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
- 6. The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

INDEPENDENT AUDITOR'S REPORT To the Board of Directors of Sanofi India Limited Report on the Consolidated Financial Results Page 3 of 4

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

- 7. Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.
- 8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the consolidated financial results/financial information, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls. (Refer paragraph 13 below)
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors.

INDEPENDENT AUDITOR'S REPORT To the Board of Directors of Sanofi India Limited Report on the Consolidated Financial Results Page 4 of 4

- We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
- 10. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

11. The consolidated financial results includes the unaudited financial information of one subsidiary, whose financial information reflect total revenue of Rs. Nil, total net loss after tax of Rs. 2 million, and total comprehensive loss of Rs. 2 million for the period from January 01, 2024 to May 31, 2024, and cash outflow (net) of Rs. 30 million for the period from January 01, 2024 to May 31, 2024, as considered in the consolidated financial results. These financial information are unaudited and have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Management, these financial information are not material to the Group.

Our opinion on the Consolidated Financial Results is not modified in respect of the above matter with respect to the financial information certified by the Board of Directors.

- 12. The Financial Results include the results for the quarter ended December 31, 2024 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which are neither subject to limited review nor audited by us.
- 13. The consolidated annual financial results dealt with by this report have been prepared for the express purpose of filing with National Stock Exchange of India Limited and BSE Limited. These results are based on and should be read with the audited consolidated financial statements of the group, for the year ended December 31, 2024 on which we have issued an unmodified audit opinion vide our report dated February 27, 2025.

For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026E/ E-300009

R RAMDAS Date: 2025.02.27

ARUNKUMA Digitally signed by ARUNKUMAR RAMDAS 21:07:10 +05'30'

Arunkumar Ramdas Partner

Membership Number: 112433 UDIN: 25112433BMOUXD9289

Place: Mumbai

Date: February 27, 2025

Registered Office: Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072. Corporate Identity Number: L24239MH1956PLC009794

Tel no: (91-22) 28032000 Fax No: (91-22) 28032846 Website: www.sanofiindialtd.com Email: igrc.sil@sanofi.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024

₹ in Million

Particulars	Quarter ended 31.12.2024 (Unaudited) (Refer Note 4	Quarter ended 30.09.2024 (Unaudited) (Refer Note 4)	Quarter ended 31.12.2023 (Unaudited) (Refer Note 4	Year ended 31.12.2024 (Audited) (Refer Note 4)	Year ended 31.12.2023 (Audited) (Refer Note 4)
Continuing Operations	and 9)	,	and 9)	,	,
1. Revenue from Operations	5,149	5,240	4,692	20,132	19,961
2. Other Income	59	23	94	165	612
3. Total Income (1+2)	5,208	5,263	4,786	20,297	20,573
4. Expenses					
(a) Cost of Materials Consumed (b) Purchases of stock in trade (c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods (d) Employee benefits expense (e) Finance costs (f) Depreciation and amortisation expense (g) Other expenses	1,027 2,385 (914) 538 4 96 930	931 2,018 (349) 567 4 90 876	783 1,278 133 725 4 93 777	3,548 5,643 602 2,402 15 367 3,029	3,439 8,933 (2,837) 2,807 17 365 2,742
Total Expenses	4,066	4,137	3,793	15,606	15,466
5. Profit before exceptional items and tax from continuing operations (3-4)	1,142	1,126	993	4,691	5,107
6. Exceptional items (Refer note 6)	80	-	-	(377)	178
7. Profit before tax from continuing operations (5+6)	1,222	1,126	993	4,314	5,285
8. Tax expense from continuing operations Current Tax Deferred Tax	279 30	310 (6)	271 25	1,258 (81)	1,634 5
9. Profit for the period /year from continuing operations (7-8)	913	822	697	3,137	3,646
10. Profit before tax from discontinued operations	-	-	895	1,310	3,170
11. Tax expense from discontinued operations	-	-	215	314	787
12. Profit for the period /year from discontinued operations (10-11)	-	-	680	996	2,383
13. Profit for the period /year (9+12)	913	822	1,377	4,133	6,029
14. Other comprehensive income (OCI) (Net of Tax) from continuing operations	72	-	(13)	72	(13)
15. Other comprehensive income (OCI) (Net of Tax) from discontinued operations	-	-	-	-	-
16. Total Other comprehensive income (OCI) (Net of Tax) (14+15)	72	-	(13)	72	(13)
17. Total comprehensive income for the period/year (13+16)	985	822	1,364	4,205	6,016
18. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230
19. Other equity	-	-	-	8,376	9,922
20. Basic and diluted earnings per share (not annualised) (in ₹) Continuing Operations Discontinued Operations Continuing and Discontinued Operations	39.64 - 39.64	35.69 - 35.69	30.26 29.53 59.79	136.21 43.25 179.46	158.31 103.47 261.78

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 27, 2025

ARUNKUMA ARUNKUMAR R RAMDAS Date: 2025.02.27

Digitally signed by RAMDAS 21:07:45 +05'30'



CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

₹ in Million

Addition Refer Note 6	CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES		₹ in Million
Addition Refer Note 6			
ASSTIS Non-current assets Non-current assets Non-current assets Non-current assets Non-current assets 181 133 445 161		December 31, 2024	December 31, 2023
ASSETS Non-current assets Property, plant and equipment 2,558 2,54 556 16,20184 work in progress 181 133 134 133 134 1		Audited	Audited
Non-current assets		(Refer Note 6)	(Refer Note 6)
Property plant and equipment	ASSETS	,	
Sample S	Non-current assets		
Sample S	Property, plant and equipment	2 558	2 544
Right-of-use assets			
Infangible assets 13			
Intangible assets under development			
Financial assets		13	
(i) Other financial assets (ii) Other financial assets (iii) Other financial assets (iii) Other financial assets (iii) Other financial assets (iii) Other non-current assets (iventories (iventories (iventories (iventories) (iventories (iventories) (iventories		- 1	26
(ii) Other financial assets 127			
Income tax assets (net)		- 1	-
Deferred tax assets (net)	(ii) Other financial assets	127	111
Deferred tax assets (net)	Income tax assets (net)	1,375	1,194
Other non-current Assets 4,850 4,668 Current assets 4,850 4,668 Inventories 1,998 6,638 Financial assets 2,300 1,31 (ii) Cash and cash equivalents 2,838 3,344 (iii) Bank Balances other than (ii) above 110 126 (iv) Loans 10 15 (v) Other financial Assets 452 2,73 Other current assets 550 36 Total current assets 11,268 12,488 TOTAL ASSETS 16,118 17,144 EQUITY AND LIABILITIES 230 230 Equity have capital 230 230 Other equity 8,376 9,92 Total equity 8,606 10,152 LIABILITIES 10 135 Non-current liabilities 140 135 Inancial liabilities 140 135 Employee benefit obligations 16 30 Deferred tax liabilities (net) 3 3 (i) Total ou			, - -
Total non-current assets 4,850 4,668 Current assets 4,998 6,638 Financial assets 4,998 6,638 Financial assets 2,300 1,311 (ii) Cash and cash equivalents 2,838 3,944 (iii) Bank Balances other than (ii) above 110 112 (iv) Usans 10 112 (v) Other financial Assets 452 7 Other current assets 560 36 Total current assets 11,268 12,486 TOTAL ASSETS 16,118 17,148 EQUITY AND LIABILITIES 20 20 Equity share capital 230 230 Other equity 3,376 9,922 Total equity 8,606 10,152 Lasse liabilities 140 1.35 Financial liabilities 140 1.35 Equity share capital 30 30 Equity share capital 21 21 Equity share capital 230 23 Equity share capit			55
Current assets Inventories			
Inventories		4,030	4,000
Financial assets 2,300 1,31	Current assets		
Financial assets 2,300 1,31	Inventories	4,998	6,638
(i)) Trade receivables (i)) Cash and cash equivalents (ii) Bank Balances other than (ii) above (iii) Bank Balances other than (ii) above (iv) Loans (v) Other financial Assets (452 77 100 110 110 110 110 110 110 110 110	Financial assets	, , , , , ,	,,,,,
(ii) Cash and cash equivalents (iii) Bank Balances other than (ii) above (iv) Loans (iv) Other financial Assets (iv) Other current assets (iv) Other financial Insibilities (iv) Other financial I		2.300	1.317
(iii) Bank Balances other than (ii) above 110 12 (iv) Loans 10 15 (v) Other financial Assets 452 76 Other current assets 560 365 Total current assets 11,268 12,488 TOTAL ASSETS 16,118 17,144 EQUITY AND LIABILITIES Equity share capital 230 230 Other equity 8,376 9,922 Total equity 8,606 10,152 LIABILITIES 8,606 10,152 Leas liabilities 140 13 Financial liabilities 140 13 Employee benefit obligations 180 30 Deferred tax liabilities (net) 320 483 Current liabilities 320 483 Current liabilities 53 5; (ii) Trade payables 221 28 (a) Total outstanding dues of micro enterprises and small enterprises 3,842 2,63 (iii) Other financial liabilities 3,44 1,6 Provisions 1,185 1,34 Employee benefit obligations			
(iv) Loans (v) Other financial Assets (v) Other financial Isobilities (v) Other financia			
(v) Other financial Assets			
Other current assets 560 363 Total current assets 11,268 12,486 TOTAL ASSETS 16,118 17,148 EQUITY AND LIABILITIES 230 230 Equity Share capital 230 230 Other equity 8,376 9,922 Total equity 8,606 10,152 LIABILITIES Non-current liabilities 140 135 Financial liabilities 180 300 Employee benefit obligations 180 30 Deferred tax liabilities (net) - 33 Total non-current liabilities 320 483 Current liabilities 53 55 (ii) Lease liabilities 53 55 (iii) Trade payables 53 55 (iii) Other financial liabilities 221 28 (iii) Other financial liabilities 3,842 2,63 (iii) Other financial liabilities 3,44 1,67 Provisions 1,185 1,1,85 Employee benefit obligations 540			
Total current assets	1		
TOTAL ASSETS			
EQUITY AND LIABILITIES Equity Share capital 230 230 Other equity 8,376 9,922 Total equity 8,606 10,152 LIABILITIES Non-current liabilities Financial liabilities Employee benefit obligations (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iii) Other fin	Total current assets	11,268	12,480
EQUITY AND LIABILITIES Equity Share capital 230 230 Other equity 8,376 9,922 Total equity 8,606 10,152 LIABILITIES Non-current liabilities Financial liabilities Employee benefit obligations (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iii) Other fin			
Equity Equity share capital 230 230 Other equity 8,376 9,922 Total equity 8,606 10,152 LIABILITIES 8,606 10,152 Non-current liabilities 4 1.33 Financial liabilities 140 1.33 Employee benefit obligations 180 30 Deferred tax liabilities (net) - 3 Total non-current liabilities 320 483 Current liabilities 3 5 Financial liabilities 53 5 (ii) Trade payables 53 5 (ii) Trade payables 221 283 (b) Total outstanding dues of micro enterprises and small enterprises 221 283 (b) Total outstanding dues of creditors other than micro enterprises and small enterprises 3,842 2,633 (iii) Other financial liabilities 3,44 166 Provisions 1,185 1,34 Employee benefit obligations 540 9,98 Current tax liabilities 48 9,98	TOTAL ASSETS	16,118	17,148
Equity Equity share capital 230 230 Other equity 8,376 9,922 Total equity 8,606 10,152 LIABILITIES 8,606 10,152 Non-current liabilities 4 1.33 Financial liabilities 140 1.33 Employee benefit obligations 180 30 Deferred tax liabilities (net) - 3 Total non-current liabilities 320 483 Current liabilities 3 5 Financial liabilities 53 5 (ii) Trade payables 53 5 (ii) Trade payables 221 283 (b) Total outstanding dues of micro enterprises and small enterprises 221 283 (b) Total outstanding dues of creditors other than micro enterprises and small enterprises 3,842 2,633 (iii) Other financial liabilities 3,44 166 Provisions 1,185 1,34 Employee benefit obligations 540 9,98 Current tax liabilities 48 9,98			
Equity share capital Other equity 230			
Other equity 8,376 9,92: Total equity 8,606 10,152 LIABILITIES Non-current liabilities 140 135 Financial liabilities 140 135 Employee benefit obligations 180 307 Deferred tax liabilities (net) 320 483 Current liabilities 53 483 Current liabilities 53 55 Financial liabilities 53 55 (i) Lease liabilities 53 55 (ii) Trade payables 221 283 (a) Total outstanding dues of micro enterprises and small enterprises 221 283 (iii) Other financial liabilities 3,842 2,63 (iii) Other financial liabilities 3,842 2,63 Employee benefit obligations 1,185 1,34 Employee benefit obligations 540 925 Current tax liabilities (net) 959 1,019 Other current liabilities 48 9 Total current liabilities 7,192 6,513 <td> Equity</td> <td></td> <td></td>	Equity		
Other equity 8,376 9,92: Total equity 8,606 10,152 LIABILITIES Non-current liabilities 140 135 Financial liabilities 140 135 Employee benefit obligations 180 307 Deferred tax liabilities (net) 320 483 Current liabilities 53 483 Current liabilities 53 55 Financial liabilities 53 55 (i) Lease liabilities 53 55 (ii) Trade payables 221 283 (a) Total outstanding dues of micro enterprises and small enterprises 221 283 (iii) Other financial liabilities 3,842 2,63 (iii) Other financial liabilities 3,842 2,63 Employee benefit obligations 1,185 1,34 Employee benefit obligations 540 925 Current tax liabilities (net) 959 1,019 Other current liabilities 48 9 Total current liabilities 7,192 6,513 <td>Equity share capital</td> <td>230</td> <td>230</td>	Equity share capital	230	230
Reserves and surplus 8,376 9,922 Total equity 8,606 10,152 LIABILITIES Non-current liabilities Financial liabilities Lease liabilities Lease liabilities 140 133 Employee benefit obligations 180 307 Total non-current liabilities (i) Lease liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Finologie benefit obligations Finalcial liabilities (ii) Lease liabilities (iii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Finalcial liabilities (iii) Other financial liabilities (iii) Other finan			
Total equity LIABILITIES Non-current liabilities Financial liabilities Lease liabilities Lease liabilities Supplyee benefit obligations Ciji) Cater financial liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (iii) Other financial liabilities Financial liabilities (b) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of reditors other than micro enterprises and small enterprises (iii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other financial liabilities (iiii) Other fi		g 376	9 922
LIABILITIES Non-current liabilities Financial liabilities Lease liabilities Lease liabilities 140 139 Employee benefit obligations Deferred tax liabilities (net) - 33 Total non-current liabilities Financial liabilities Financial liabilities Financial liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (iii) Trade payables (a) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities	· · · · · · · · · · · · · · · · · · ·		
Non-current liabilities Financial liabilities Lease liabilities Employee benefit obligations Deferred tax liabilities (net) Total non-current liabilities Current liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (iii) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities	lotal equity	8,606	10,152
Non-current liabilities Financial liabilities Lease liabilities Employee benefit obligations Deferred tax liabilities (net) Total non-current liabilities Current liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (iii) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities	l		
Financial liabilities Lease liabilities Lease liabilities 140 139 Employee benefit obligations Deferred tax liabilities (net) Total non-current liabilities Current liabilities Financial liabilities (i) Lease liabilities (ii) Trade payables (iii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Financial liabilities 153 151 283 291 293 291 293 291 293 293 294 393 291 293 291 293 293 294 295 201 293 295 201 295 201 201 201 201 201 201 201 201 201 201			
Lease liabilities 140 133 Employee benefit obligations 180 307 Deferred tax liabilities (net) - 33 Total non-current liabilities 320 483 Current liabilities (i) Lease liabilities 5 (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (iii) Other financial liabilities 344 166 Provisions 1,185 1,345 Employee benefit obligations 540 926 Current tax liabilities (net) 959 1,015 Other current liabilities 48 96 Total current liabilities 48 996 Total current liabilities 7,192 6,513			
Employee benefit obligations Deferred tax liabilities (net) Total non-current liabilities Current liabilities Financial liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities 7,192 6,513	Financial liabilities		
Deferred tax liabilities (net) Total non-current liabilities Current liabilities Financial liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities 7,192 6,513	Lease liabilities	140	139
Deferred tax liabilities (net) Total non-current liabilities Current liabilities Financial liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities 7,192 6,513	Employee benefit obligations	180	307
Current liabilities Financial liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities Financial liabilities 53 52 221 283 283 284 2,633 3,842 2,633 2,633 2,633 2,633 2,633 2,633 2,633 2,633 2,633 2,633 2,633 2,633 2,		- 1	37
Financial liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities 53 48 221 283 243 3,842 2,63 344 167 1,185 1,185 1,34: 540 928 Current tax liabilities (net) Other current liabilities 48 97 7,192 6,513	Total non-current liabilities	320	483
Financial liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities 53 48 221 283 243 3,842 2,63 344 167 1,185 1,185 1,34: 540 928 Current tax liabilities (net) Other current liabilities 48 97 7,192 6,513			
Financial liabilities (i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities 53 48 221 283 243 3,842 2,63 344 167 1,185 1,185 1,34: 540 928 Current tax liabilities (net) Other current liabilities 48 97 7,192 6,513	Current liabilities		
(i) Lease liabilities (ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities 53 221 283 2,63 3,842 2,63 344 167 1,185 1,34: 540 928 540 959 1,01: 0ther current liabilities 48 96 7,192 6,513			
(ii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities 3,842 2,633 (iii) Other financial liabilities 3,844 167 Provisions 1,185 1,345 Employee benefit obligations 540 928 Current tax liabilities (net) 959 1,015 Other current liabilities 48 96 Total current liabilities 7,192 6,513		E2	E1
(a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities 221 283 3,842 2,632 344 167 349 1,185 1,349 928 1,019 049 959 1,019 059 1,019 06,513]	21
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities Provisions Employee benefit obligations Current tax liabilities (net) Other current liabilities Total current liabilities 3,842 2,633 344 167 1,185 1,349 928 929 1,011 959 1,011 96,513			202
(iii) Other financial liabilities 344 167 Provisions 1,185 1,34 Employee benefit obligations 540 928 Current tax liabilities (net) 959 1,019 Other current liabilities 48 96 Total current liabilities 7,192 6,513			
Provisions 1,185 1,34 Employee benefit obligations 540 928 Current tax liabilities (net) 959 1,019 Other current liabilities 48 96 Total current liabilities 7,192 6,513			
Employee benefit obligations 540 928 Current tax liabilities (net) 959 1,011 Other current liabilities 48 96 Total current liabilities 7,192 6,513			167
Current tax liabilities (net)9591,019Other current liabilities4896Total current liabilities7,1926,513			1,341
Other current liabilities 48 96 Total current liabilities 7,192 6,513			928
Total current liabilities 7,192 6,513	Current tax liabilities (net)	959	1,015
	Other current liabilities		96
	Total current liabilities	7,192	6,513
TOTAL COURTY AND LIADTUITIES			
101AL CQUITT AND LIADILITIES 10,118 11,148	TOTAL EQUITY AND LIABILITIES	16,118	17,148

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report R RAMDAS dated February 27, 2025

ARUNKUMA Digitally signed by ARUNKUMAR RAMDAS

TR RAMDAS Date: 2025.02.27
21:08:50 +05'30'

RACHID Digitally signed by RACHID AYARI AYARI Date: 2025.02.27 20:33:38 +05'30'

₹ in Million

		₹ in Million
Particulars	Year ended December 31, 2024	
Turucum3	Audited	Audited (Refer note 4 and 6)
	(Refer flote 4 and 6)	(Refer flote 4 and 6)
Cash flow From operating activities		
Profit before tax:	1 211	F 20F
Continuing Operations	4,314	5,285
Discontinued Operations Profit before income tax including Discontinued Operations	1,310	3,170
Profit before income tax including Discontinued Operations	5,624	8,455
Adjustment for Continuing and Discontinued Operations :		
Depreciation and amortization expenses	382	396
Unrealised exchange (gain) / loss (net)	6	(4)
(Gain) on sale of property, plant and equipment / asset held for sale (net of incidental expenses)	(5)	
Gain on termination/retirement of lease (net)		(13)
Finance costs	15	17
Interest income	(166)	(475)
Share based payment	12	61
Provision for bad and doubtful debts (net)	2	(8)
Provision for doubtful advances and deposits (net)	5	(4)
Operating profit before working capital changes	5,875	8,207
Adjustments for (increase) / decrease in operating assets Non-current financial assets	(21)	40
Other non-current assets	(21)	40
	(7) 687	(2 550)
Inventories Trade receivables		(2,558)
	(1,270)	(7)
Current financial assets and loans	(357)	(7)
Other current assets	(898)	100
Adjustments for increase / (decrease) in operating liabilities	(142)	(260)
Employee benefit obligations	(143)	
Trade payables	1,662	(669)
Current financial liabilities Other current liabilities & provisions	134 (73)	40 (175)
Cash generated from operations	5,589	4,717
Taxes paid (Net of Refund)	(974)	
Net cash inflow from operating activities (A)	4,615	2,304
nec cash limow from operating activities (x)	4,015	2,504
Cash flow from Investing activities		
Sale proceeds of property, plant and equipment and assets held for sale (net of incidental expenses)	6	243
Interest received	166	475
Purchase of property, plant and equipment and Intangible assets	(364)	(343)
Net cash (outflow) / inflow for investing activities (B)	(192)	375
Cash flow from financing activities		
Principal elements of lease payments	(63)	
Interest paid	(15)	(17)
Dividend paid	(3,846)	(8,683)
Net cash (outflow) for financing activities (C)	(3,924)	(8,783)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	499	(6,104)
Effect of Exchange differences on cash and cash equivalents held in foreign currency	*	*
Cash and Cash Equivalents at the beginning of the year/period Less: Cash Transferred pursuant to demerger (Refer Note 6)	3,945 (1,606)	10,049
Cash and Cash Equivalents at the end of the year	2,838	3,945
Non- cash financing and investing activities (D)		1
Acquisition of Right-of-use assets	66	106
Components of Cash and Cash Equivalents		
Cash and Cash Equivalents	2,838	3,945

^{*} denotes figure less than a million.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 27, 2025





Notes:

- 1. The Consolidated financial results for the reporting period include the results for Sanofi India Limited (the "Company") and its subsidiary Sanofi Consumer Healthcare India Limited. The Company and its subsidiary are together referred as 'the Group' (Refer notes 4 & 5 below).
- 2. The above Results have been reviewed by the Audit Committee at its meeting held on February 26, 2025 and approved by the Board of Directors of the Company at its Meeting held on February 27, 2025.
- 3. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- 4. The Board on May 10, 2023, had approved a Scheme of arrangement under Sections 230 to 232 of the Companies Act, 2013 ("Scheme"), to demerge the Consumer Healthcare business of the Company into its wholly owned subsidiary Sanofi Consumer Healthcare India Limited ("SCHIL"). Pursuant to receipt of necessary statutory approvals and in accordance with the Scheme, the Company has demerged its Consumer Healthcare business effective June 1, 2024, with the Appointed Date being June 1, 2023 as approved by NCLT under the Scheme. Consequently, the financial results of the Consumer Healthcare business for the period upto May 31, 2024 and quarter and year ended December 31, 2023 have been presented as discontinued operations to reflect the impact of this demerger.
- 5. The Company has prepared and presented the consolidated financial results, for its investment in SCHIL as set out in note 4 effective quarter ended June 30, 2023. Consolidated financial results for the Quarter and year ended December 31, 2023 includes financial results of SCHIL with effect from May 10, 2023 being its date of incorporation. For the period from Jan 1, 2024 to May 31, 2024 there were no operations in SCHIL except expenses amounting to ₹2 million. The shareholders of the Company were allotted equity shares of SCHIL in accordance with the Scheme. Accordingly, from June 1, 2024, SCHIL ceased to be a subsidiary of the Company.
- 6. Pursuant to the demerger, the Company has derecognized from its books of account, the carrying amount of assets and liabilities as on May 31, 2024 pertaining to the Consumer Healthcare business transferred to SCHIL. The excess of the carrying amount of assets transferred over the carrying amount of liabilities transferred aggregating to ₹1,902 million has been debited to reserves in accordance with the Scheme.
- 7. Exceptional item for the quarter ended December 31, 2024 of ₹ 80 million relates to part reversal of personnel separation cost. For the year ended December 31, 2024 exceptional cost relates to personnel separation cost amounting to ₹377 million net of above reversal. Exceptional item for the year ended December 31, 2023 includes profit on sale of property amounting to ₹255 million offset by personnel separation cost amounting to ₹77 million.
- 8. For the continuing business, the Board has recommended maintaining the final Dividend at ₹117 per equity share of ₹ 10 for the year ended December 31, 2024 . The dividend will be paid after approval of shareholders at ensuing Annual General Meeting of the Company.
- 9. The figures for the quarter ended December 31, 2024 and December 31, 2023 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2024 and December 31, 2023 and the unaudited published year-to-date figures up to September 30, 2024 and September 30, 2023 respectively, which was subject to limited review, being the date of the end of the third quarter of the said financial year.
- 10. The Company has a single business segment namely 'Pharmaceutical Business'.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 27, 2025

ARUNKUMA Digitally signed by ARUNKUMAR RAMDAS

R RAMDAS Date: 2025.02.27 21:11:12 +05'30'

February 27, 2025

SANOFI INDIA LIMITED

RACHID Digitally signed by RACHID AYARI Date: 2025.02.27 20:34:33 +05'30'

RACHID AYARI WHOLETIME DIRECTOR & CFO DIN: 10408699

Annexure B

Details of the party (listed entity In case monies are due to either party as a result of								Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details disclosed only once, during the reporting period when such transaction was undertaken. It of In case any financial indebtedness is incurred to make or give loans, inter-corporate							ity/subsidiary. These details need to I		
	Details of the party (listed entity /subsidiary) entering into the	Details of the counterparty				Value of the related party	Value of transaction	In case monies are due to the tran			s is incurred to make or g advances or investment			Details of the loan	s, inter-corporate deposi	ts, advances or investments	
Sr No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Value of the related party transaction as approved by the audit committee			Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/unsecured	Purpose for which the funds will be utilised by the ultimate recipient o funds (endusage)
1	Sanofi India Limited	Sanofi-aventis Singapore Pte.Ltd.	Common Control	Sale of goods or services	5168.00	0.00	2042.00	795.00	1156.00								
2	Sanofi India Limited	Sanofi-Aventis Deutschland GmbH	Common Control	Sale of goods or services	0.00	0.00	0.00	0.00	0.00								
3	Sanofi India Limited		Common Control	Sale of goods or services	100.00	0.00	2.00	135.00	0.00								
4	Sanofi India Limited	Sanofi Consumer Healthcare India Limited		Sale of goods or services	359.00				268.00								
5	Sanofi India Limited	sanofi-aventis Singapore Pte.Ltd.	Common Control	Purchase of goods or services Purchase of goods or	5657.00	0.00	4230.00	188.00	2356.00								
	Sanofi India Limited	Sanofi Healthcare India Pvt. Ltd.	Common Control	services Purchase of goods or	837.00				151.00								
	Sanofi India Limited	Sanofi Healthcare India Pvt. Ltd.	Common Control	services Purchase of goods or	0.00				0.00								
		Francopia Sanofi Consumer Healthcare India	Common Control	services Purchase of goods or	619.00				160.00								
	Sanofi India Limited	Limited	Common Control	services	0.00				0.00								
		Opella healthcare UK ltd Sanofi Winthrop Industries S. A.		Any other transaction Any other transaction	0.00				0.00								
	Sanofi India Limited Sanofi India Limited	Sanofi Consumer Healthcare India		Any other transaction Any other transaction	100.00				0.00								
		Limited Sanofi-Aventis Gestion SA		Any other transaction	100.00												
14	Sanofi India Limited			Any other transaction	0.00				0.00								
15	Sanofi India Limited			Any other transaction	250.00				19.00								
16	Sanofi India Limited			Any other transaction	20.00 250.00				3.00 14.00								
		Opella Healthcare India Private Ltd.		Any other transaction Any other transaction	70.00				14.00								
		Sanofi Consumer Healthcare India Ltd.		Any other transaction	253.00				24.00								
20	Sanofi India Limited	Sanofi Consumer Healthcare India Ltd.	Common Control	Any other transaction	30.00	0.00	21.00	0.00	0.00								
				Any other transaction	1980.00	0.00			153.00								
				Any other transaction		0.00			0.00								
	Sanofi India Limited Sanofi India Limited			Any other transaction Any other transaction	100.00 20.00				0.00								
		Sanofi Consumer Healthcare Private		Any other transaction	0.00				0.00								
		EUROAPI Germany GmbH		Any other transaction	50.00				0.00								
	Sanofi India Limited		Common Control	Any other transaction	30.00				7.00								
	Sanofi India Limited Sanofi India Limited	Sanofi US Services Inc. Sanofi Consumer Healthcare India Limited	Common Control Common Control	Any other transaction Any other transaction	50.00 317.00				3.00								
30	Sanofi India Limited	SANOFI AVENTIS MALAYSIA SDN BHD	Common Control	Any other transaction	50.00	0.00	8.00	0.00	8.00								
31	Sanofi India Limited	EUROAPI Germany GmbH	Common Control	Any other transaction	50.00	0.00	1.00	0.00	0.00								
				Any other transaction	70.00				0.00								
				Any other transaction	50.00				0.00								
35				Any other transaction Loan	40.00	0.00	0.00	43.00 0.00	0.00								
				Loan		0.00			0.00								
	Sanofi India Limited	Sanofi Healthcare India Pvt. Ltd.	Common Control	Loan		0.00			0.00								
38	Sanofi India Limited	Sanofi Healthcare India Pvt. Ltd.	Common Control	Interest received		0.00		0.00	0.00								
	Sanofi India Limited Sanofi India Limited	Hoechst GmbH, Germany, holding		Dividend paid Dividend paid		0.00			0.00								
		Mr. Aditya Narayan	Key management personnel of	Any other transaction		0.00			0.00								
42	Sanofi India Limited	Ms. Usha Thorat	entity or parent Key management personnel of entity or parent	Any other transaction		0.00	1.00	0.00	0.00								
43	Sanofi India Limited	Mr. Rahul Bhatnagar	Key management personnel of	Any other transaction		0.00	1.00	0.00	0.00								
44	Sanofi India Limited	Mr. Aditya Narayan	entity or parent Key management personnel of entity or parent	Any other transaction		0.00	0.00	0.00	0.00								
45	Sanofi India Limited	Ms. Usha Thorat	You man agament personnel of	Any other transaction		0.00	0.00	0.00	0.00								
46	Sanofi India Limited	Mr. Rahul Bhatnagar	V	Any other transaction		0.00	0.00	0.00	0.00								
47	Sanofi India Limited	MS RADHIKA SHAH	V	Remuneration		0.00	6.00	0.00	0.00								
48	Sanofi India Limited	MR RODOLFO HROSZ	Key management personnel of entity or parent	Remuneration		0.00	15.00	0.00	0.00	_							
49	Sanofi India Limited	MR RACHID AYARI	Key management personnel of entity or parent	Remuneration		0.00	8.00	0.00	0.00								-
		MS RENE AMONKAR	entity or parent	Remuneration		0.00			0.00								
			You man agament percented of	Any other transaction		0.00			0.00								
		MR RODOLFO HROSZ	entity or parent	Any other transaction		0.00			0.00								
53		MR RACHID AYARI	entity or parent	Any other transaction		0.00		0.00	0.00								
	Total value of transaction during	g trie reporting period					8446										